On the public citation graph
mTOR-targeted therapy of cancer with rapamycin derivatives
0 signed · 675 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/bies.10031openalex-snapshot
Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K
inferredcites →https://doi.org/10.1002/eji.1830250239openalex-snapshot
FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells
inferredcites →https://doi.org/10.1007/978-1-4615-1809-9_5openalex-snapshot
Mechanism of action of rapamycin: New insights into the regulation of G1-phase progression in eukaryotic cells
inferredcites →https://doi.org/10.1007/bf00336467openalex-snapshot
Renal effects of rapamycin in the spontaneously hypertensive rat
inferredcites →https://doi.org/10.1016/0929-7855(96)00534-2openalex-snapshot
Inhibitory effect of wortmannin on phosphatidylinositol 3-kinase-mediated cellular events
inferredcites →https://doi.org/10.1016/j.bbrc.2003.09.132openalex-snapshot
Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer
inferredcites →https://doi.org/10.1016/j.cub.2004.06.054openalex-snapshot
Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton
inferredcites →https://doi.org/10.1016/s0009-9120(98)00048-4openalex-snapshot
Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update
inferredcites →https://doi.org/10.1016/s0014-5793(02)03582-2openalex-snapshot
ATP depletion increases phosphorylation of elongation factor eEF2 in adult cardiomyocytes independently of inhibition of mTOR signalling
inferredcites →https://doi.org/10.1016/s0014-5793(99)01094-7openalex-snapshot
Dissociation of the eukaryotic initiation factor‐4E/4E‐BP1 complex involves phosphorylation of 4E‐BP1 by an mTOR‐associated kinase
inferredcites →https://doi.org/10.1016/s0041-1345(03)00211-2openalex-snapshot
Sirolimus: its discovery, biological properties, and mechanism of action
inferredcites →https://doi.org/10.1016/s0041-1345(03)00215-xopenalex-snapshot
Use of rapamycin-impregnated stents in coronary arteries
inferredcites →https://doi.org/10.1016/s0092-8674(00)81683-9openalex-snapshot
The Hallmarks of Cancer
inferredcites →https://doi.org/10.1016/s0968-0004(00)89056-8openalex-snapshot
Wortmannin as a unique probe for an intracellular signalling protein, phosphoinositide 3-kinase
inferredcites →https://doi.org/10.1016/s1525-0016(03)00170-9openalex-snapshot
MDA-7 negatively regulates the β-catenin and PI3K signaling pathways in breast and lung tumor cells
inferredcites →https://doi.org/10.1023/b:appt.0000045781.46314.e2openalex-snapshot
Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma
inferredcites →https://doi.org/10.1038/ki.1996.417openalex-snapshot
Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506
inferredcites →https://doi.org/10.1038/ng0597-64openalex-snapshot
Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
inferredcites →https://doi.org/10.1038/nm0202-128openalex-snapshot
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
inferredcites →https://doi.org/10.1038/nm1052openalex-snapshot
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
inferredcites →https://doi.org/10.1038/sj.gt.3301641openalex-snapshot
A novel conditional Akt ‘survival switch’ reversibly protects cells from apoptosis
inferredcites →https://doi.org/10.1038/sj.onc.1204751openalex-snapshot
Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase
inferredcites →https://doi.org/10.1038/sj.onc.1205555openalex-snapshot
Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells
inferredcites →https://doi.org/10.1038/sj.onc.1205923openalex-snapshot
Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma
inferredcites →https://doi.org/10.1038/sj.onc.1206388openalex-snapshot
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
inferredcites →https://doi.org/10.1046/j.1365-2133.2001.04376.xopenalex-snapshot
Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial
inferredcites →https://doi.org/10.1073/pnas.012605299openalex-snapshot
A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus
inferredcites →https://doi.org/10.1073/pnas.080068597openalex-snapshot
The immunosuppressive macrolide RAD inhibits growth of human Epstein–Barr virus-transformed B lymphocytes in vitro and in vivo : A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders
inferredcites →https://doi.org/10.1073/pnas.171076798openalex-snapshot
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
inferredcites →https://doi.org/10.1074/jbc.270.2.815openalex-snapshot
Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells
inferredcites →https://doi.org/10.1074/jbc.270.46.27531openalex-snapshot
TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-Rapamycin
inferredcites →https://doi.org/10.1074/jbc.271.50.31824openalex-snapshot
Inhibition of the Phosphatidylinositol 3-Kinase/p70S6-Kinase Pathway Induces B16 Melanoma Cell Differentiation
inferredcites →https://doi.org/10.1074/jbc.273.23.14484openalex-snapshot
Amino Acid Sufficiency and mTOR Regulate p70 S6 Kinase and eIF-4E BP1 through a Common Effector Mechanism
inferredcites →https://doi.org/10.1074/jbc.m110782200openalex-snapshot
4E-binding Proteins, the Suppressors of Eukaryotic Initiation Factor 4E, Are Down-regulated in Cells with Acquired or Intrinsic Resistance to Rapamycin
inferredcites →https://doi.org/10.1091/mbc.01-12-0584openalex-snapshot
Akt Maintains Cell Size and Survival by Increasing mTOR-dependent Nutrient Uptake
inferredcites →https://doi.org/10.1093/annonc/mdg248openalex-snapshot
Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors
inferredcites →https://doi.org/10.1093/emboj/cdf391openalex-snapshot
Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV‐1 envelope
inferredcites →https://doi.org/10.1093/hmg/7.3.507openalex-snapshot
Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation
inferredcites →https://doi.org/10.1096/fasebj.14.7.895openalex-snapshot
Increased phosphoinositide 3‐kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo
inferredcites →https://doi.org/10.1096/fj.01-0658comopenalex-snapshot
Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) ‐dependent signaling
inferredcites →https://doi.org/10.1097/00007691-199312000-00004openalex-snapshot
Therapeutic Monitoring of Rapamycin
inferredcites →https://doi.org/10.1097/00007691-199512000-00020openalex-snapshot
Rapamycin: Distribution, Pharmacokinetics, and Therapeutic Range Investigations
inferredcites →https://doi.org/10.1097/00007890-199305000-00033openalex-snapshot
EFFECT OF A SHORT COURSE OF RAPAMYCIN, CYCLOSPORIN A, AND DONOR-SPECIFIC TRANSFUSION ON RAT CARDIAC ALLOGRAFT SURVIVAL
inferredcites →https://doi.org/10.1097/00007890-199307000-00003openalex-snapshot
EFFECTS OF RAPAMYCIN IN EXPERIMENTAL ORGAN ALLOGRAFTING
inferredcites →https://doi.org/10.1097/00007890-199707150-00007openalex-snapshot
SDZ RAD, A NEW RAPAMYCIN DERIVATIVE
inferredcites →https://doi.org/10.1097/00007890-199707150-00008openalex-snapshot
SDZ RAD, A NEW RAPAMYCIN DERIVATIVE
inferredcites →https://doi.org/10.1097/00007890-199910270-00007openalex-snapshot
A PHASE I STUDY OF A 4-WEEK COURSE OF SDZ-RAD (RAD) IN QUIESCENT CYCLOSPORINE-PREDNISONE-TREATED RENAL TRANSPLANT RECIPIENTS1,2
inferredcites →https://doi.org/10.1097/00007890-200004150-00012openalex-snapshot
EFFECT OF TACROLIMUS (FK506) AND SIROLIMUS (RAPAMYCIN) MONO- AND COMBINATION THERAPY IN PROLONGATION OF RENAL ALLOGRAFT SURVIVAL IN THE MONKEY1
inferredcites →https://doi.org/10.1097/00007890-200009270-00015openalex-snapshot
SIROLIMUS (RAPAMYCIN) HALTS AND REVERSES PROGRESSION OF ALLOGRAFT VASCULAR DISEASE IN NON-HUMAN PRIMATES1
inferredcites →https://doi.org/10.1097/00007890-200110150-00001openalex-snapshot
RAPAMYCIN: CLINICAL RESULTS AND FUTURE OPPORTUNITIES1
inferredcites →https://doi.org/10.1097/01.tp.0000063934.89714.19openalex-snapshot
Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses
inferredcites →https://doi.org/10.1101/gad.12.4.502openalex-snapshot
4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway
inferredcites →https://doi.org/10.1124/mol.54.5.815openalex-snapshot
Studies on the Mechanism of Resistance to Rapamycin in Human Cancer Cells
inferredcites →https://doi.org/10.1126/science.1063518openalex-snapshot
Mammalian TOR: A Homeostatic ATP Sensor
inferredcites →https://doi.org/10.1128/mcb.16.12.6744openalex-snapshot
Rapamycin Resistance Tied to Defective Regulation of p27 Kip1
inferredcites →https://doi.org/10.1128/mcb.19.2.1346openalex-snapshot
Cyclin D1 Expression Mediated by Phosphatidylinositol 3-Kinase through mTOR-p70S6K-Independent Signaling in Growth Factor-Stimulated NIH 3T3 Fibroblasts
inferredcites →https://doi.org/10.1128/mcb.20.24.9138-9148.2000openalex-snapshot
Forkhead Transcription Factor FKHR-L1 Modulates Cytokine-Dependent Transcriptional Regulation of p27 KIP1
inferredcites →https://doi.org/10.1158/0008-5472.can-04-3137openalex-snapshot
Effects of the Mammalian Target of Rapamycin Inhibitor CCI-779 Used Alone or with Chemotherapy on Human Prostate Cancer Cells and Xenografts
inferredcites →https://doi.org/10.1158/0008-5472.can-3554-2openalex-snapshot
Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells
inferredcites →https://doi.org/10.1158/1078-0432.ccr-03-0043openalex-snapshot
Determinants of Rapamycin Sensitivity in Breast Cancer Cells
inferredcites →https://doi.org/10.1161/01.cir.99.16.2164openalex-snapshot
Inhibition of Intimal Thickening After Balloon Angioplasty in Porcine Coronary Arteries by Targeting Regulators of the Cell Cycle
inferredcites →https://doi.org/10.1172/jci119038openalex-snapshot
Rapamycin inhibits vascular smooth muscle cell migration.
inferredcites →https://doi.org/10.1182/blood-2002-10-3014openalex-snapshot
The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade
inferredcites →https://doi.org/10.1182/blood.v92.11.4487openalex-snapshot
Deletions in the Long Arm of Chromosome 10 in Lymphomas With t(14;18): A Pathogenetic Role of the Tumor Suppressor Genes PTEN/MMAC1 and MXI1?
inferredcites →https://doi.org/10.1182/blood.v92.11.4487.423a57g_4487_4489openalex-snapshot
Deletions in the long arm of chromosome 10 in lymphomas with t(14;18): a pathogenetic role of the tumor supressor genes PTEN/MMAC1 and MXI1?
inferredcites →https://doi.org/10.1200/jco.2004.08.116openalex-snapshot
Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer
inferredcites →https://doi.org/10.1200/jco.2004.08.185openalex-snapshot
Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma
inferredcites →https://doi.org/10.1200/jco.2004.22.14_suppl.3002openalex-snapshot
Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM
inferredcites →https://doi.org/10.1200/jco.2004.22.14_suppl.3076openalex-snapshot
Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies
inferredcites →https://doi.org/10.1677/erc.0.0080249openalex-snapshot
mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.
inferredcites →https://doi.org/10.2165/00002018-199716040-00004openalex-snapshot
Clinically Significant Drug Interactions with New Immunosuppressive Agents
inferredcites →https://doi.org/10.2165/00003088-200140080-00002openalex-snapshot
Clinical Pharmacokinetics of Sirolimus
inferredcites →https://doi.org/10.2337/diabetes.50.2.353openalex-snapshot
Metabolic Regulation by Leucine of Translation Initiation Through the mTOR-Signaling Pathway by Pancreatic β-Cells
inferredcites →https://doi.org/10.2741/grantopenalex-snapshot
Roles of Erbb family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival
inferredcites →https://doi.org/10.3816/cbc.2003.n.018openalex-snapshot
Mammalian Target of Rapamycin: A New Molecular Target for Breast Cancer
inferredcites →https://doi.org/10.7164/antibiotics.28.721openalex-snapshot
Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.
inferredcites →https://doi.org/10.7164/antibiotics.28.727openalex-snapshot
Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.
inferredcites →https://doi.org/10.7164/antibiotics.31.539openalex-snapshot
Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation.
inferredcites →https://doi.org/10.7164/antibiotics.32.630openalex-snapshot
Rapamycin (AY-22,989), a new antifungal antibiotic. IV. Mechanism of action.
inferredcites →https://doi.org/10.7164/antibiotics.37.1231openalex-snapshot
Activity of rapamycin (AY-22,989) against transplanted tumors.
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4130574openalex-extracted
NRF3-Mediated mTORC1 Activation Arginine-Dependently Contributes to Cancer Cell Viability Through Mitochondrial Quality Control
inferred← citeshttps://doi.org/10.1002/1878-0261.13377openalex-snapshot
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1002/9780470475959.ch6openalex-snapshot
Molecular Pathology as a Way to Find the Right Dose for a Drug
inferred← citeshttps://doi.org/10.1002/9781118873434.ch95openalex-snapshot
General Malignancy after Organ Transplantation
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm136openalex-snapshot
Oral Complications of Cancer and Their Treatment
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm136.pub2openalex-snapshot
Oral Complications of Cancer and Their Treatment
inferred← citeshttps://doi.org/10.1002/adma.201201498openalex-snapshot
Multistage pH‐Responsive Liposomes for Mitochondrial‐Targeted Anticancer Drug Delivery
inferred← citeshttps://doi.org/10.1002/ajh.21664openalex-snapshot
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
inferred← citeshttps://doi.org/10.1002/ajh.22263openalex-snapshot
Sorafenib, a multikinase inhibitor, is effective in vitro against non‐hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin
inferred← citeshttps://doi.org/10.1002/ana.20784openalex-snapshot
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
inferred← citeshttps://doi.org/10.1002/biot.201500075openalex-snapshot
Chemical manipulation of the mTORC1 pathway in industrially relevant CHOK1 cells enhances production of therapeutic proteins
inferred← citeshttps://doi.org/10.1002/bit.24567openalex-snapshot
Rapamycin treatment inhibits CHO cell death in a serum‐free suspension culture by autophagy induction
inferred← citeshttps://doi.org/10.1002/cbin.10179openalex-snapshot
Inhibition of m TOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation
inferred← citeshttps://doi.org/10.1002/cbin.10820openalex-snapshot
The post‐therapeutic effect of rapamycin in mild traumatic brain‐injured rats ensuing in the upregulation of autophagy and mitophagy
inferred← citeshttps://doi.org/10.1002/ccr3.4537openalex-snapshot
Oral manifestations and dental care management of a young patient with lymphangioma of the tongue: A case report
inferred← citeshttps://doi.org/10.1002/cncr.24696openalex-snapshot
Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients
inferred← citeshttps://doi.org/10.1002/ctm2.147openalex-snapshot
STXBP6, reciprocally regulated with autophagy, reduces triple negative breast cancer aggressiveness
inferred← citeshttps://doi.org/10.1002/ddr.70167openalex-snapshot
Targeting mTOR Kinase for Cancer Treatment: A Comprehensive Review With Clinical Insights
inferred← citeshttps://doi.org/10.1002/gcc.20357openalex-snapshot
Combination of a rapamycin analog (CCI‐779) and interferon‐γ is more effective than single agents in treating a mouse model of tuberous sclerosis complex
inferred← citeshttps://doi.org/10.1002/hon.766openalex-snapshot
Regulation of apoptosis and proliferation in Ewing's sarcoma—opportunities for targeted therapy
inferred← citeshttps://doi.org/10.1002/ijc.24749openalex-snapshot
Celecoxib reduces the effects of acute and chronic UVB exposure in mice treated with therapeutically relevant immunosuppressive drugs
inferred← citeshttps://doi.org/10.1002/jat.3393openalex-snapshot
Autophagy function and its relationship to pathology, clinical applications, drug metabolism and toxicity
inferred← citeshttps://doi.org/10.1002/jbt.21603openalex-snapshot
Rapamycin Plays a Neuroprotective Effect after Spinal Cord Injury via Anti‐Inflammatory Effects
inferred← citeshttps://doi.org/10.1002/jnr.23358openalex-snapshot
Rapamycin prevents N‐methyl‐D‐aspartate‐induced retinal damage through an ERK‐dependent mechanism in rats
inferred← citeshttps://doi.org/10.1002/jps.21286openalex-snapshot
Antiangiogenic Drugs: Current Knowledge and New Approaches to Cancer Therapy
inferred← citeshttps://doi.org/10.1002/lary.26780openalex-snapshot
Sirolimus as treatment for 19 patients with refractory cervicofacial lymphatic malformation
inferred← citeshttps://doi.org/10.1002/lio2.241openalex-snapshot
Clinical application of molecular genetics in lymphatic malformations
inferred← citeshttps://doi.org/10.1002/lt.21668openalex-snapshot
Report of the Paris Consensus Meeting on Expanded Criteria Donors in Liver Transplantation
inferred← citeshttps://doi.org/10.1002/mc.23248openalex-snapshot
MYC‐binding lncRNA EPIC1 promotes AKT‐mTORC1 signaling and rapamycin resistance in breast and ovarian cancer
inferred← citeshttps://doi.org/10.1002/mc.23628openalex-snapshot
A systems biology approach and in vitro experiment indicated Rapamycin targets key cancer and cell cycle‐related genes and miRNAs in triple‐negative breast cancer cells
inferred← citeshttps://doi.org/10.1002/med.20059openalex-snapshot
Anti‐angiogenic drugs: from bench to clinical trials
inferred← citeshttps://doi.org/10.1002/pbc.23124openalex-snapshot
Sirolimus for the treatment of complicated vascular anomalies in children
inferred← citeshttps://doi.org/10.1002/pbc.24866openalex-snapshot
Treatment of a tongue lymphangioma with sirolimus after failure of surgical resection and propranolol
inferred← citeshttps://doi.org/10.1002/pbc.25886openalex-snapshot
Gorham-Stout Disease of the Skull Base With Hearing Loss: Dramatic Recovery and Antiangiogenic Therapy
inferred← citeshttps://doi.org/10.1002/pbc.28088openalex-snapshot
Topical sirolimus for the treatment of cutaneous manifestations of vascular anomalies: A case series
inferred← citeshttps://doi.org/10.1002/pbc.28162openalex-snapshot
Sirolimus for the treatment of juvenile nasopharyngeal angiofibroma
inferred← citeshttps://doi.org/10.1002/pros.20752openalex-snapshot
RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid
inferred← citeshttps://doi.org/10.1002/pros.21172openalex-snapshot
Targeting tumor metabolism with 2‐deoxyglucose in patients with castrate‐resistant prostate cancer and advanced malignancies
inferred← citeshttps://doi.org/10.1002/prp2.70126openalex-snapshot
The Effects of Different Administration Regimens of Berberine Hydrochloride on the Pharmacokinetics of Sirolimus in Rats
inferred← citeshttps://doi.org/10.1002/ptr.6862openalex-snapshot
Hispidulin: A novel natural compound with therapeutic potential against human cancers
inferred← citeshttps://doi.org/10.1002/slct.202504509openalex-snapshot
Rational Design of Benzofuran‐Based mTOR Inhibitors for Head and Neck Cancer: A Synergistic 3D‐QSAR, Molecular Docking, and DFT Approach
inferred← citeshttps://doi.org/10.1007/16833_2024_397openalex-snapshot
New-Generation Drug Delivery Systems (DDSs) in Anticancer Strategies: Impact of Autophagy and Its Modulation
inferred← citeshttps://doi.org/10.1007/978-1-4020-6554-5_5openalex-snapshot
Therapeutic Targeting of Death Pathways in Cancer: Mechanisms for Activating Cell Death in Cancer Cells
inferred← citeshttps://doi.org/10.1007/978-1-4419-0410-2_1openalex-snapshot
Overview of the Molecular Genetics and Molecular Chemotherapy of GBM
inferred← citeshttps://doi.org/10.1007/978-1-4419-7203-3_18openalex-snapshot
Effects and Therapeutic Potential of Targeting Dysregulated Signaling Axes in Squamous Cell Carcinoma: Another Kinase of Transcription and Mammalian Target of Rapamycin
inferred← citeshttps://doi.org/10.1007/978-1-59745-215-1_15openalex-snapshot
Novel Agents and New Paradigms for Colorectal Cancer Beyond EGFR and VEGF
inferred← citeshttps://doi.org/10.1007/978-1-59745-337-0_13openalex-snapshot
Molecular Targets in Ovarian Cancer and Endometrial Cancer
inferred← citeshttps://doi.org/10.1007/978-1-60327-271-1_3openalex-snapshot
mTOR Signaling in Angiogenesis
inferred← citeshttps://doi.org/10.1007/978-1-60327-424-1_8openalex-snapshot
Targeted Therapy in Lymphoma
inferred← citeshttps://doi.org/10.1007/978-1-61779-430-8_9openalex-snapshot
Evaluation of rapamycin-induced cell death.
inferred← citeshttps://doi.org/10.1007/978-2-8178-0021-9_5openalex-snapshot
Thérapeutiques ciblées dans le traitement des tumeurs solides
inferred← citeshttps://doi.org/10.1007/978-2-8178-0492-7_5openalex-snapshot
The Role of mTOR Inhibitors in Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/978-3-319-23246-1_4openalex-snapshot
The Impact of Cancer Treatments on Aging
inferred← citeshttps://doi.org/10.1007/978-3-319-34211-5_6openalex-snapshot
Combination Therapies Targeting the PI3K/AKT/mTOR Pathways
inferred← citeshttps://doi.org/10.1007/978-3-319-43121-5_22openalex-snapshot
Novel Therapies and Future Directions in Treatment of Musculoskeletal Sarcomas
inferred← citeshttps://doi.org/10.1007/978-3-319-66200-8_8openalex-snapshot
Cutaneous Reactions to Targeted Anticancer Agents
inferred← citeshttps://doi.org/10.1007/978-3-540-31209-3_7openalex-snapshot
The Mammalian Target of Rapamycin Kinase and Tumor Growth Inhibition
inferred← citeshttps://doi.org/10.1007/978-3-662-46709-1_18openalex-snapshot
Lymphatic Malformation (LM) (Extratruncular): Lymphangioma
inferred← citeshttps://doi.org/10.1007/978-3-7643-8595-8_2openalex-snapshot
Total synthesis studies on macrocyclic pipecolic acid natural products: FK506, the antascomicins and rapamycin
inferred← citeshttps://doi.org/10.1007/978-981-15-2321-2_2openalex-snapshot
Pathogenesis, Genetics, and Molecular Developments in Vascular Lesion Therapy and Diagnosis
inferred← citeshttps://doi.org/10.1007/978-981-97-7274-2_11openalex-snapshot
The Road from Laboratory to Patient
inferred← citeshttps://doi.org/10.1007/s00280-007-0609-2openalex-snapshot
Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines
inferred← citeshttps://doi.org/10.1007/s00280-011-1788-4openalex-snapshot
Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
inferred← citeshttps://doi.org/10.1007/s00280-013-2118-9openalex-snapshot
Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors
inferred← citeshttps://doi.org/10.1007/s00280-014-2637-zopenalex-snapshot
Autophagy modulation: a target for cancer treatment development
inferred← citeshttps://doi.org/10.1007/s00280-015-2770-3openalex-snapshot
Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives
inferred← citeshttps://doi.org/10.1007/s00345-023-04526-5openalex-snapshot
Bladder cancer immunomodulatory effects of intravesical Nitazoxanide, Rapamycin, Thalidomide and Bacillus Calmette–Guérin (BCG)
inferred← citeshttps://doi.org/10.1007/s00383-022-05320-xopenalex-snapshot
Lymphatic malformations in children: retrospective review of surgical and interventional management
inferred← citeshttps://doi.org/10.1007/s00384-009-0664-8openalex-snapshot
Combined inhibition of Dnmt and mTOR signaling inhibits formation and growth of colorectal cancer
inferred← citeshttps://doi.org/10.1007/s00432-011-1037-6openalex-snapshot
Down-regulation of JAK1 by RNA interference inhibits growth of the lung cancer cell line A549 and interferes with the PI3K/mTOR pathway
inferred← citeshttps://doi.org/10.1007/s00432-011-1123-9openalex-snapshot
Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer
inferred← citeshttps://doi.org/10.1007/s00432-017-2407-5openalex-snapshot
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives
inferred← citeshttps://doi.org/10.1007/s10269-009-1064-yopenalex-snapshot
Carcinomes à cellules rénales: de la pathologie aux voies moléculaires de la carcinogenèse
inferred← citeshttps://doi.org/10.1007/s10495-013-0904-9openalex-snapshot
Superoxide activates mTOR–eIF4E–Bax route to induce enhanced apoptosis in leukemic cells
inferred← citeshttps://doi.org/10.1007/s10528-023-10343-7openalex-snapshot
Significance of CD80 as a Prognostic and Immunotherapeutic Biomarker in Lung Adenocarcinoma
inferred← citeshttps://doi.org/10.1007/s10549-006-9395-5openalex-snapshot
Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro
inferred← citeshttps://doi.org/10.1007/s10549-007-9746-xopenalex-snapshot
Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables
inferred← citeshttps://doi.org/10.1007/s10549-010-0967-zopenalex-snapshot
The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study
inferred← citeshttps://doi.org/10.1007/s10549-010-1315-zopenalex-snapshot
Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer
inferred← citeshttps://doi.org/10.1007/s10555-011-9290-3openalex-snapshot
Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors
inferred← citeshttps://doi.org/10.1007/s10620-008-0605-3openalex-snapshot
Antitumoral Activity of Rapamycin Mediated Through Inhibition of HIF-1alpha and VEGF in Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1007/s10620-014-3417-7openalex-snapshot
Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1007/s10637-010-9558-4openalex-snapshot
Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs
inferred← citeshttps://doi.org/10.1007/s10637-021-01093-7openalex-snapshot
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study
inferred← citeshttps://doi.org/10.1007/s11011-013-9401-7openalex-snapshot
Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma
inferred← citeshttps://doi.org/10.1007/s11033-016-4089-5openalex-snapshot
Suppression of mTOR signaling pathway promotes bone marrow mesenchymal stem cells differentiation into osteoblast in degenerative scoliosis: in vivo and in vitro
inferred← citeshttps://doi.org/10.1007/s11033-020-05808-6openalex-snapshot
Association of mTOR pathway with risk of gastric cancer in male smoker with potential prognostic significance
inferred← citeshttps://doi.org/10.1007/s11033-023-08283-xopenalex-snapshot
Molecular and therapeutic insights of rapamycin: a multi-faceted drug from Streptomyces hygroscopicus
inferred← citeshttps://doi.org/10.1007/s11060-007-9371-xopenalex-snapshot
Specific mTOR inhibitor rapamycin enhances cytotoxicity induced by alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU) in human U251 malignant glioma cells
inferred← citeshttps://doi.org/10.1007/s11064-015-1564-7openalex-snapshot
mTOR and Erk1/2 Signaling in the Cerebrospinal Fluid-Contacting Nucleus is Involved in Neuropathic Pain
inferred← citeshttps://doi.org/10.1007/s11427-008-0080-2openalex-snapshot
Mammalian target of rapamycin pathway inhibition enhances the effects of 5-aza-dC on suppressing cell proliferation in human gastric cancer cell lines
inferred← citeshttps://doi.org/10.1007/s11523-007-0054-5openalex-snapshot
The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts
inferred← citeshttps://doi.org/10.1007/s11523-007-0058-1openalex-snapshot
Molecular targeted therapy for advanced hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1007/s11523-009-0128-7openalex-snapshot
Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors
inferred← citeshttps://doi.org/10.1007/s11523-012-0217-xopenalex-snapshot
Relevance of angiogenesis in neuroendocrine tumors
inferred← citeshttps://doi.org/10.1007/s11605-012-1951-1openalex-snapshot
Treatment of Liver Metastases in Patients with Digestive Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/s11864-006-0038-1openalex-snapshot
Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies
inferred← citeshttps://doi.org/10.1007/s11864-011-0148-2openalex-snapshot
New Treatment Options for Patients with Advanced Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1007/s11864-011-0180-2openalex-snapshot
mTOR Inhibitors and its Role in the Treatment of Head and Neck Squamous Cell Carcinoma
inferred← citeshttps://doi.org/10.1007/s11864-013-0246-4openalex-snapshot
Evolving Treatment Strategies for Management of Carcinoid Tumors
inferred← citeshttps://doi.org/10.1007/s11912-009-0028-0openalex-snapshot
Progress in the treatment of neuroendocrine tumors
inferred← citeshttps://doi.org/10.1007/s11912-009-0047-xopenalex-snapshot
New agents in acute myeloid leukemia: Beyond cytarabine and anthracyclines
inferred← citeshttps://doi.org/10.1007/s12026-008-8038-9openalex-snapshot
Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease
inferred← citeshttps://doi.org/10.1007/s12031-015-0568-8openalex-snapshot
Poloxamer 188 Attenuates Cerebral Hypoxia/Ischemia Injury in Parallel with Preventing Mitochondrial Membrane Permeabilization and Autophagic Activation
inferred← citeshttps://doi.org/10.1007/s12032-009-9311-zopenalex-snapshot
Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases
inferred← citeshttps://doi.org/10.1007/s12035-016-0071-4openalex-snapshot
Ketamine Exhibits Different Neuroanatomical Profile After Mammalian Target of Rapamycin Inhibition in the Prefrontal Cortex: the Role of Inflammation and Oxidative Stress
inferred← citeshttps://doi.org/10.1007/s12035-019-01794-4openalex-snapshot
Iron Overload Impairs Autophagy: Effects of Rapamycin in Ameliorating Iron-Related Memory Deficits
inferred← citeshttps://doi.org/10.1007/s12094-007-0116-2openalex-snapshot
Pharmacodynamics: biological activity of targeted therapies in clinical trials
inferred← citeshttps://doi.org/10.1007/s12094-009-0394-yopenalex-snapshot
Comprehensive lung injury pathology induced by mTOR inhibitors
inferred← citeshttps://doi.org/10.1007/s12185-010-0607-8openalex-snapshot
Current treatment strategy and new agents in mantle cell lymphoma
inferred← citeshttps://doi.org/10.1007/s12325-010-0045-2openalex-snapshot
Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors
inferred← citeshttps://doi.org/10.1007/s12328-025-02183-2openalex-snapshot
Giant hepatic hemangioma in a Japanese adult patient reduced by sirolimus therapy
inferred← citeshttps://doi.org/10.1007/s12558-013-0270-4openalex-snapshot
Mécanismes et pathologies du vieillissement
inferred← citeshttps://doi.org/10.1007/s12664-012-0257-2openalex-snapshot
Pancreatic neuroendocrine tumors
inferred← citeshttps://doi.org/10.1007/s12672-018-0343-8openalex-snapshot
Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells
inferred← citeshttps://doi.org/10.1007/s12672-025-02827-2openalex-snapshot
Tumor-infiltrating nerves: unraveling the role of cancer neuroscience in tumorigenesis, disease progression, and emerging therapies
inferred← citeshttps://doi.org/10.1007/s13277-015-3409-zopenalex-snapshot
MicroRNA-199a-3p suppresses glioma cell proliferation by regulating the AKT/mTOR signaling pathway
inferred← citeshttps://doi.org/10.1007/s13277-015-3725-3openalex-snapshot
Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models
inferred← citeshttps://doi.org/10.1007/s13277-016-5083-1openalex-snapshot
mTOR inhibitors in urinary bladder cancer
inferred← citeshttps://doi.org/10.1007/s13318-019-00562-yopenalex-snapshot
Dose Escalation Study to Assess the Pharmacokinetic Parameters of a Nano-amorphous Oral Sirolimus Formulation in Healthy Volunteers
inferred← citeshttps://doi.org/10.1007/s40265-015-0489-4openalex-snapshot
Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products
inferred← citeshttps://doi.org/10.1016/b978-0-12-817868-3.00013-5openalex-snapshot
Autophagy in head and neck cancer therapy
inferred← citeshttps://doi.org/10.1016/b978-0-12-818549-0.00011-xopenalex-snapshot
Anticancer drugs acting on signaling pathways, part 2: Inhibitors of serine-threonine kinases and miscellaneous signaling pathways
inferred← citeshttps://doi.org/10.1016/b978-0-12-822951-4.00014-xopenalex-snapshot
Application of molecular genetics to congenital vascular anomalies
inferred← citeshttps://doi.org/10.1016/b978-0-323-90300-4.00089-6openalex-snapshot
Drug discovery and development
inferred← citeshttps://doi.org/10.1016/b978-0-323-99879-6.00001-8openalex-snapshot
Combined targeting autophagy and metabolism for cancer therapy
inferred← citeshttps://doi.org/10.1016/b978-0-443-15260-3.00004-1openalex-snapshot
Mitophagy inducers as potential therapeutic agents
inferred← citeshttps://doi.org/10.1016/b978-0-443-23932-8.00010-8openalex-snapshot
Targeting autophagy with pharmacological small molecules to treat human diseases
inferred← citeshttps://doi.org/10.1016/b978-0-444-52824-7.00009-3openalex-snapshot
Drugs That Inhibit Signalling Pathways for Tumor Cell Growth and Proliferation
inferred← citeshttps://doi.org/10.1016/b978-0-444-62649-3.00010-7openalex-snapshot
Drugs That Inhibit Signaling Pathways for Tumor Cell Growth and Proliferation
inferred← citeshttps://doi.org/10.1016/b978-1-4557-0268-8.00041-5openalex-snapshot
Extended Criteria Donors
inferred← citeshttps://doi.org/10.1016/bs.pmch.2018.01.002openalex-snapshot
Current Trends in Macrocyclic Drug Discovery and beyond -Ro5
inferred← citeshttps://doi.org/10.1016/j.addr.2016.10.002openalex-snapshot
Molecular targeting of hypoxia in radiotherapy
inferred← citeshttps://doi.org/10.1016/j.ajog.2006.10.872openalex-snapshot
Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model
inferred← citeshttps://doi.org/10.1016/j.apmt.2022.101364openalex-snapshot
Microenvironment-activatable cascaded responsive carbonized polymer dots as a theranostic platform for precise rapamycin delivery to potentiate the synergy of chemotherapy and γδ T cells-mediated immunotherapy against tumor
inferred← citeshttps://doi.org/10.1016/j.bbacli.2015.11.003openalex-snapshot
The mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trials
inferred← citeshttps://doi.org/10.1016/j.bbagen.2006.07.016openalex-snapshot
Effects of rapamycin on cell proliferation and phosphorylation of mTOR and p70S6K in HepG2 and HepG2 cells overexpressing constitutively active Akt/PKB
inferred← citeshttps://doi.org/10.1016/j.bbapap.2007.08.015openalex-snapshot
Role of mTOR in physiology and pathology of the nervous system
inferred← citeshttps://doi.org/10.1016/j.bbcan.2005.08.001openalex-snapshot
K-ras as a target for cancer therapy
inferred← citeshttps://doi.org/10.1016/j.bbcan.2010.01.004openalex-snapshot
CXCR6/CXCL16 functions as a regulator in metastasis and progression of cancer
inferred← citeshttps://doi.org/10.1016/j.bbrc.2014.04.018openalex-snapshot
Combined therapeutic potential of nuclear receptors with receptor tyrosine kinase inhibitors in lung cancer
inferred← citeshttps://doi.org/10.1016/j.bcp.2013.09.022openalex-snapshot
Novel compound 1,3-bis (3,5-dichlorophenyl) urea inhibits lung cancer progression
inferred← citeshttps://doi.org/10.1016/j.bcp.2017.11.021openalex-snapshot
Modulating autophagy in cancer therapy: Advancements and challenges for cancer cell death sensitization
inferred← citeshttps://doi.org/10.1016/j.biomaterials.2012.10.034openalex-snapshot
Rapamycin encapsulated in dual-responsive micelles for cancer therapy
inferred← citeshttps://doi.org/10.1016/j.biomaterials.2013.01.030openalex-snapshot
Intracellular delivery and antitumor effects of pH-sensitive liposomes based on zwitterionic oligopeptide lipids
inferred← citeshttps://doi.org/10.1016/j.bioorg.2021.104907openalex-snapshot
Structure-based modification of pyrazolone derivatives to inhibit mTORC1 by targeting the leucyl-tRNA synthetase-RagD interaction
inferred← citeshttps://doi.org/10.1016/j.bpg.2012.12.002openalex-snapshot
Neuroendocrine tumours of the small intestine
inferred← citeshttps://doi.org/10.1016/j.brainres.2014.01.017openalex-snapshot
RETRACTED: Rapamycin induces of protective autophagy in vascular endothelial cells exposed to oxygen–glucose deprivation
inferred← citeshttps://doi.org/10.1016/j.bulcan.2015.09.011openalex-snapshot
La voie de signalisation PI3K-AKT-mTOR : description, développement thérapeutique, résistances, marqueurs prédictifs/pronostiques et applications thérapeutiques en cancérologie
inferred← citeshttps://doi.org/10.1016/j.canlet.2006.11.008openalex-snapshot
Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer
inferred← citeshttps://doi.org/10.1016/j.canlet.2008.11.036openalex-snapshot
Chemopreventive efficacy of rapamycin on Peutz–Jeghers syndrome in a mouse model
inferred← citeshttps://doi.org/10.1016/j.canlet.2010.07.020openalex-snapshot
RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase
inferred← citeshttps://doi.org/10.1016/j.cbi.2016.10.014openalex-snapshot
CWF-145, a novel synthetic quinolone derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced apoptosis through the inhibition of Akt/mTOR pathway
inferred← citeshttps://doi.org/10.1016/j.ccr.2005.08.008openalex-snapshot
The Akt-mTOR tango and its relevance to cancer
inferred← citeshttps://doi.org/10.1016/j.ccr.2007.06.005openalex-snapshot
Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy
inferred← citeshttps://doi.org/10.1016/j.ccr.2008.12.017openalex-snapshot
mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
inferred← citeshttps://doi.org/10.1016/j.cell.2006.01.016openalex-snapshot
TOR Signaling in Growth and Metabolism
inferred← citeshttps://doi.org/10.1016/j.cell.2025.03.036openalex-snapshot
CD36-mediated endocytosis of proteolysis-targeting chimeras
inferred← citeshttps://doi.org/10.1016/j.cellsig.2014.09.003openalex-snapshot
Transmembrane signaling in Saccharomyces cerevisiae as a model for signaling in metazoans: State of the art after 25years
inferred← citeshttps://doi.org/10.1016/j.clcc.2017.03.011openalex-snapshot
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study)
inferred← citeshttps://doi.org/10.1016/j.clinre.2012.09.010openalex-snapshot
Digestive neuroendocrine tumors (DNET): The era of targeted therapies
inferred← citeshttps://doi.org/10.1016/j.coms.2023.09.010openalex-snapshot
Terminology and Classifications of Vascular Lesions Based on Molecular Identification
inferred← citeshttps://doi.org/10.1016/j.copbio.2006.09.006openalex-snapshot
Therapeutic potential of natural product signal transduction agents
inferred← citeshttps://doi.org/10.1016/j.coph.2011.05.003openalex-snapshot
Neuroprotective, immunosuppressant and antineoplastic properties of mTOR inhibitors: current and emerging therapeutic options
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2005.07.001openalex-snapshot
Shared biology of GVHD and GVT effects: Potential methods of separation
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2005.11.002openalex-snapshot
Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2006.06.008openalex-snapshot
Kinase inhibitors in the treatment of renal cell carcinoma
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2007.04.002openalex-snapshot
Targeting mTOR signaling in lung cancer
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2008.01.007openalex-snapshot
Targeting AMPK: A new therapeutic opportunity in breast cancer
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2014.08.007openalex-snapshot
The evolving field of kinase inhibitors in thyroid cancer
inferred← citeshttps://doi.org/10.1016/j.ctrv.2007.01.002openalex-snapshot
ASCO 2006 highlights: Targeted therapy for renal cell carcinoma
inferred← citeshttps://doi.org/10.1016/j.ctrv.2009.12.002openalex-snapshot
Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research
inferred← citeshttps://doi.org/10.1016/j.ctrv.2009.12.004openalex-snapshot
Exploiting cellular pathways to develop new treatment strategies for AML
inferred← citeshttps://doi.org/10.1016/j.ddmec.2005.05.013openalex-snapshot
Allogeneic graft-versus-tumor effects: Mechanistic insights and therapeutic promise
inferred← citeshttps://doi.org/10.1016/j.ddmec.2005.05.021openalex-snapshot
Akt, hexokinase, mTOR: Targeting cellular energy metabolism for cancer therapy
inferred← citeshttps://doi.org/10.1016/j.drudis.2006.12.008openalex-snapshot
Targeting mammalian target of rapamycin (mTOR) for health and diseases
inferred← citeshttps://doi.org/10.1016/j.drudis.2011.02.001openalex-snapshot
Cytoplasmic ATM protein kinase: an emerging therapeutic target for diabetes, cancer and neuronal degeneration
inferred← citeshttps://doi.org/10.1016/j.drudis.2019.05.030openalex-snapshot
Revisiting mTOR inhibitors as anticancer agents
inferred← citeshttps://doi.org/10.1016/j.drudis.2021.12.009openalex-snapshot
A molecular perspective for the use of type IV tyrosine kinase inhibitors as anticancer therapeutics
inferred← citeshttps://doi.org/10.1016/j.ecl.2010.09.006openalex-snapshot
Novel Anticancer Agents in Clinical Trials for Well-Differentiated Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1016/j.ejca.2006.03.015openalex-snapshot
Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus
inferred← citeshttps://doi.org/10.1016/j.ejca.2008.06.028openalex-snapshot
Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies
inferred← citeshttps://doi.org/10.1016/j.ejca.2012.02.053openalex-snapshot
RETRACTED: Effects of the combination of RAD001 and docetaxel on breast cancer stem cells
inferred← citeshttps://doi.org/10.1016/j.ejmech.2013.12.020openalex-snapshot
Benzofuran derivatives as a novel class of inhibitors of mTOR signaling
inferred← citeshttps://doi.org/10.1016/j.eursup.2012.05.002openalex-snapshot
Epidemiology, Aetiology, and Pathogenesis of Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1016/j.gtc.2011.06.007openalex-snapshot
Liver Transplantation in the 21st Century: Expanding the Donor Options
inferred← citeshttps://doi.org/10.1016/j.healun.2007.03.010openalex-snapshot
Is There a Role for Proliferation Signal/mTOR Inhibitors in the Prevention and Treatment of De Novo Malignancies After Heart Transplantation? Lessons Learned From Renal Transplantation and Oncology
inferred← citeshttps://doi.org/10.1016/j.healun.2010.09.005openalex-snapshot
Infection and malignancy after pediatric heart transplantation: The role of induction therapy
inferred← citeshttps://doi.org/10.1016/j.hoc.2008.07.006openalex-snapshot
New Drugs for the Treatment of Lymphoma
inferred← citeshttps://doi.org/10.1016/j.hoc.2011.05.003openalex-snapshot
Systemic Therapy for Metastatic Non–Clear-Cell Renal Cell Carcinoma: Recent Progress and Future Directions
inferred← citeshttps://doi.org/10.1016/j.hoc.2015.09.002openalex-snapshot
Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors
inferred← citeshttps://doi.org/10.1016/j.humpath.2010.05.025openalex-snapshot
Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas
inferred← citeshttps://doi.org/10.1016/j.humpath.2013.03.006openalex-snapshot
Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2025.145439openalex-snapshot
Chitosan coated ZnO/Tio2/Gd2O3 nano composites for improved rapamycin delivery in non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.ijpharm.2010.11.005openalex-snapshot
Perivascular sirolimus-delivery system
showing the first 200 of 594 · page through all 594
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.